translational biomarkers

Cognitive Synergy Corporation is a biotechnology company developing novel small-molecule therapies for Alzheimer's disease and related neurodegenerative disorders. Its lead candidate is designed to restore synaptic health while reducing amyloid and tau pathology, aiming to be a disease-modifying treatment. The company integrates translational biomarkers, pharmacology, and behavioral outcomes and is progressing its small molecule through IND-enabling studies toward early clinical trials.

Read more

IND-enabling studiespharmacologypreclinical researchsmall molecule drug discovery